Regenxbio Inc. (RGNX) shares are gaining more than 7 percent on Tuesday morning trade after the clinical-stage biotechnology reported additional interim safety and efficacy data in the Phase I/II Affinity Duchenne trial of RGX-202 in patients of 4-11 years old with Duchenne muscular dystrophy.
The company said while there is an insufficient level of data in boys above 7 years, RGX-202 at dose level 2 demonstrated significantly increased microdystrophin expression in a 12-year-old patient.
Currently, shares are at $23.10, up 7.68 percent from the previous close of $21.36 on a volume of 880,468.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.